Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 436 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A | EXPERIMENTAL | AMG 436 monotherapy dose escalation. |
| Part 1B: Food Effect Substudy | EXPERIMENTAL | Participants will receive AMG 436 under fasted and fed conditions (United States only). |
| Part 2 | EXPERIMENTAL | AMG 436 + combination dose escalation. |
| Part 3 | EXPERIMENTAL | AMG 436 monotherapy Dose expansion and optimization. |
| Part 4 | EXPERIMENTAL | AMG 436 + chemotherapy combination dose expansions. |
| Name | Type | Description |
|---|---|---|
| AMG 436 | DRUG | AMG 436 will be administered. |
Inclusion Criteria: * Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). * Histologically confirmed MSI-H or dMMR metastatic or locally advanced solid tumor by local testing or central testing. * Tumor tissue (formalin-fixed, paraffin-embedded sample) archival block mu...
AMG 436 is an investigational small molecule being developed for the treatment of metastatic or locally advanced solid tumors that are microsatellite instability-high (MSI-H) or have mismatched repair deficiency (dMMR). It is currently being studied in a Phase 1 clinical trial as a monotherapy and in combination therapy.
AMG 436 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AMGN. The drug is currently in Phase 1 clinical development for the treatment of MSI-H or dMMR solid tumors.
AMG 436 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the drug as a monotherapy and in combination therapy for MSI-H or dMMR solid tumors.
AMG 436 is being studied in a Phase 1 clinical trial with the identifier NCT07403721. The trial is titled "AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors" and is currently recruiting participants. The trial is enrolling approximately 464 participants across multiple countries.
AMG 436 is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential to treat solid tumors characterized by microsatellite instability-high (MSI-H) or mismatched repair deficiency (dMMR).
The Phase 1 clinical trial of AMG 436 (NCT07403721) is being conducted in multiple countries, including the United States, Australia, Belgium, Canada, China, France, Japan, South Korea, Spain, and Taiwan. The trial is open to adults aged 18 years and older.